Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥18 years with physician diagnosis of atopic dermatitis for \>1 year as defined by American Academy of Dermatology Consensus Criteria.~* Atopic dermatitis involvement of ≥10% of body surface area at screening and baseline.~* EASI score of ≥12 at screening or ≥16 at baseline.~* IGA score of ≥3 at screening and baseline (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe)~* Baseline Pruritus Numerical Rating Scale (NRS) score for maximum itch intensity ≥3 over the previous 24 hours.~Exclusion Criteria:~* Pregnant or lactating women.~* Prior treatment with ISB 830~* Treatment with biologics~* Systemic corticosteroids, immunosuppressive/immunomodulatory drugs or phototherapy within 4 weeks of baseline~* Active chronic or acute infection requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISB 830 - Part 1 Group 1 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
- ISB 830 - Part 1 Group 2 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
- ISB 830 - Part 1 Group 3 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
- Placebo - Part 1 Group 4 (Type: PLACEBO_COMPARATOR): Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
- ISB 830 - Part 2 Group 5 (Type: EXPERIMENTAL): Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
- Placebo - Part 2 Group 6 (Type: PLACEBO_COMPARATOR): Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).